Monday, 10 July 2017, 6:30pm CEST

We kindly invite investors and analysts to participate in an analyst briefing during the International Society on Thrombosis and Hemostasis Congress (ISTH) in Berlin 8 – 13 July 2017.

During the briefing, Roche will discuss new data for emicizumab (ACE910) in hemophilia A:

HAVEN1 - phase 3 study of emicizumab (ACE910) prophylaxis in persons with hemophilia A with inhibitors

HAVEN2 - phase 3 study of emicizumab (ACE910) in pediatric persons with hemophilia A with inhibitors

Venue

Hotel Berlin, Berlin
Lützowplatz 17
10785 Berlin
Germany
map

Date/Time

Monday, 10 July 2017 @ 6:30pm CEST
The briefing will be followed by a buffet reception.

An invitation with the detailed programme and registration form will follow shortly.

Best regards,

Karl Mahler
Head of Investor Relations

Sabine Borngräber
Investor Relations Officer